Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 345,200 shares, a drop of 21.4% from the August 15th total of 439,000 shares. Based on an average daily trading volume, of 281,400 shares, the short-interest ratio is presently 1.2 days. Approximately 2.3% of the company’s stock are sold short.
Several brokerages have commented on ETTX. BMO Capital Markets reissued a “buy” rating on shares of Entasis Therapeutics in a research report on Sunday, August 29th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Entasis Therapeutics in a research report on Thursday, September 16th.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC raised its holdings in shares of Entasis Therapeutics by 55.3% in the 1st quarter. Renaissance Technologies LLC now owns 786,606 shares of the company’s stock valued at $1,683,000 after purchasing an additional 280,217 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Entasis Therapeutics by 104.7% in the 2nd quarter. Vanguard Group Inc. now owns 419,997 shares of the company’s stock valued at $1,121,000 after purchasing an additional 214,831 shares in the last quarter. Alberta Investment Management Corp acquired a new stake in shares of Entasis Therapeutics in the 2nd quarter valued at $347,000. Squarepoint Ops LLC raised its holdings in shares of Entasis Therapeutics by 53.8% in the 1st quarter. Squarepoint Ops LLC now owns 91,725 shares of the company’s stock valued at $196,000 after purchasing an additional 32,081 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Entasis Therapeutics by 53.9% in the 2nd quarter. Geode Capital Management LLC now owns 81,121 shares of the company’s stock valued at $216,000 after purchasing an additional 28,424 shares in the last quarter. Institutional investors and hedge funds own 7.04% of the company’s stock.
Entasis Therapeutics (NASDAQ:ETTX) last announced its quarterly earnings data on Wednesday, August 11th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.05). On average, research analysts expect that Entasis Therapeutics will post -1.12 earnings per share for the current year.
About Entasis Therapeutics
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Featured Story: The limitations of an equal weight rating
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.